Corresponding Author: Deborah Money, MD, University of British Columbia, C425-4500 Oak St, Vancouver, BC V6H 3N1, Canada (deborah.money@ubc.ca).
Accepted for Publication: March 29, 2022.
Published Online: May 2, 2022. doi:10.1001/jama.2022.5906
Author Contributions: Drs McClymont and Albert had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: McClymont, Albert, Boucoiran, Castillo, Fell, Poliquin, Reeve, Sprague, Crane, Elwood, Murphy-Kaulbeck, Saunders, Shah, Snelgrove, van Schalkwyk, Yudin, Money.
Acquisition, analysis, or interpretation of data: McClymont, Albert, Alton, Fell, Kuret, Reeve, Scott, Sprague, Carson, Cassell, Crane, Elwood, Joynt, Murphy, Shah, Snelgrove, van Schalkwyk, Money.
Drafting of the manuscript: McClymont, Albert, Poliquin, Reeve, Money.
Critical revision of the manuscript for important intellectual content: Albert, Alton, Boucoiran, Castillo, Fell, Kuret, Scott, Sprague, Carson, Cassell, Crane, Elwood, Joynt, Murphy, Murphy-Kaulbeck, Saunders, Shah, Snelgrove, van Schalkwyk, Yudin, Money.
Statistical analysis: Albert, Alton, Fell.
Obtained funding: McClymont, Boucoiran, Kuret, Reeve, Elwood, Money.
Administrative, technical, or material support: McClymont, Alton, Boucoiran, Kuret, Poliquin, Reeve, Sprague, Cassell, Joynt, Snelgrove, van Schalkwyk, Money.
Supervision: Boucoiran, Elwood, Murphy-Kaulbeck, Yudin, Money.
Conflict of Interest Disclosures: Dr McClymont reported receiving salary support from a Michael Smith Foundation for Health Research Trainee Award and a Canadian HIV Trials Network Postdoc Fellowship. Dr Boucoiran reported receiving grants from Fonds de Recherche en Santé du Québec, Ferring, and the Quebec Health Ministry; receiving personal fees from Fonds de Recherche en Santé du Québec; receiving nonfinancial support from Altona; and participating in randomized clinical trials for GlaxoSmithKline and Pfizer. Dr Poliquin reported receiving honoraria/consultation fees from GlaxoSmithKline, Sanofi Pasteur, and Searchlight Pharma. Dr Sprague reported receiving funding from the Ontario Ministry of Health for BORN Ontario. Dr Elwood reported receipt of personal fees for board membership from Gilead. Dr Money reported receiving nonfinancial support from the COVID-19 Immunity Task Force and grants from the Canadian Institutes for Health Research (outside the submitted work), Merck, GlaxoSmithKline, Sanofi, and Novartis. No other disclosures were reported.
Funding/Support: This project was funded by the Public Health Agency of Canada (grant 2021-HQ-000100), the Canadian Institutes for Health Research (grant 447634), and the BC Women’s Health Foundation (grant 89026 7537 RR0001).
Role of the Funder/Sponsor: As part of the review and approval of the funding applications, the Public Health Agency of Canada, the Canadian Institutes for Health Research, and the BC Women’s Health Foundation approved the design, analysis, and conduct of the study. The funders had no role in the collection, management, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Group Information: The CANCOVID-Preg Team members are listed in Supplement 2.
Additional Contributions: We acknowledge the contributing study staff (in alphabetical order): Arezou Azampanah, MSc (Women’s Health Research Institute; received compensation), Shamara Baidoobonso, PhD (Chief Public Health Office, Government of Prince Edward Island; did not receive compensation), Marc Beltempo, MD (Montreal Children’s Hospital and McGill University Health Centre; did not receive compensation), Suraya Bondy, BA (Women’s Health Research Institute; received compensation), Richard Brown, MD (McGill University; did not receive compensation), Emmanuel Bujold, MD (Université Laval; did not receive compensation), Suzanne Demers, MD (Université Laval; did not receive compensation), Karen Downing, RNBN (Women’s Health Research, Health Sciences Centre, Winnipeg; received compensation), Kaamel Hafizi, MSc (Children’s Hospital of Eastern Ontario Research Institute and Better Outcomes Registry and Network Ontario; did not receive compensation), Julie Hanna, BA (Women’s Health Research Institute; received compensation), Heather Hannah, DVM (Government of the Northwest Territories; did not receive compensation), James King, MSc (Alberta Health Services; did not receive compensation), Audrey Klassen, RN (University of Manitoba; received compensation), Carolina Lavin Venegas, MSc (Children’s Hospital of Eastern Ontario Research Institute and Better Outcomes Registry and Network Ontario; did not receive compensation), France Leduc, MD (Hôpital de la Cité-de-la-Santé & Université de Montréal; did not receive compensation), Isabelle Malhamé, MD (McGill University Health Centre; did not receive compensation), Fran Mulhall, RN (Health Sciences Centre Winnipeg; received compensation), Ali Nabeel, MD (Hôpital Maisonneuve-Rosemont; did not receive compensation), Donnette O’Brien, RN (Eastern Health; received compensation), Melanie Pastuck, BN (University of Calgary; received compensation), Bruno Piedboeuf, MD (CHU de Québec & Université Laval; did not receive compensation), Janet Slaunwhite (Dalhousie University; did not receive compensation), Suzanne Taillefer, PhD (CHU Sainte-Justine; did not receive compensation), Laurent H. Tordjman, MD (Université de Montréal and Hôpital Maisonneuve-Rosemont; did not receive compensation), Melissa Watt, CCRP (Women’s Health Research Institute; received compensation), Connie Williams, MD, PhD (McMaster University; did not receive compensation), and Bi Lan Wo, MD (Centre Hospitalier de l’Université de Montréal; did not receive compensation). We also acknowledge the Public Health Agency of Canada staff involved in the project (in alphabetical order; none received compensation): Susie Dzakpasu, PhD, Wei Luo, MSc, Stephanie Metcalfe, MSc, and Jay Onysko, MA.